article thumbnail

Promising schizophrenia drug faces tough competition

European Pharmaceutical Review

GlobalData’s report showed LY03010 is expected to launch in the US in 2024. Thus, LY03010 could be more convenient to administer and improve patient compliance by optimising the initial dosing regimen, while ensuring efficacy and safety. If successful, the drug is forecasted to reach sales of $63.5 million in 2031, representing 0.6

article thumbnail

First European ustekinumab biosimilar to Stelara approved

European Pharmaceutical Review

Ustekinumab biologic Once the European Supplementary Protection Certificate (SPC) for Stelara expires in July 2024, this will open up market entry as soon as possible for Uzpruvo, now that it is approved in Europe” Ustekinumab is a human IgG1κ monoclonal antibody (mAb). The EU ustekinumab market is worth €2.5

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves first Stelara biosimilar, Wezlana

European Pharmaceutical Review

The FDA said its approval of Wezlana is based on “a comprehensive review of scientific evidence demonstrating it is highly similar to Stelara and that there are no clinically meaningful differences between the two products in terms of safety, purity and potency.” Sustainable biosimilar competition in Europe: can it be achieved?

article thumbnail

4 Biotech Executives Share Strategies Behind Successful Fund Raises

PM360

Learn more about why each company went with its respective strategy and the current outlook for each company in 2024 and beyond. The deal is expected to close in 2024. Many investors also prioritize companies with a substantial market opportunity and a unique product, particularly in competitive markets or crowded therapeutic areas.

article thumbnail

Defining Biotech Success in a Challenging Fundraising Environment

PM360

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.

Biopharma 111
article thumbnail

Nicox glaucoma drug works, but not as well as hoped

pharmaphorum

“We believe that the top-line results as reported in and of themselves do not appear to appreciably differentiate NCX-470’s IOP-lowering competitive profile as a monotherapy” from current therapies like latanoprost and bimatoprost, he said in a research note.

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. In 2024, ARPA removes the 100% AMP cap.